the "clinical signs and abnormalities on imaging are always reversible. "
As is often the case following the initial description of a new syndrome, the boundaries of PRES were expanded as more cases were reported. The "posterior" location of the imaging findings, while common, was not universal. Lee et al. (2) from Mayo Clinic described the clinical spectrum of PRES in their series of 36 patients reported in 2008. They found that "atypical" imaging findings were common, with frontal involvement in 58% of cases and gray matter involvement in 42%. They also challenged the "reversible" label, reporting hemorrhages in 5% of cases and "foci of permanent injury" in 26%. Later reports suggested that microhemorrhages could be seen on susceptibility weighted images on more than half of patients with PRES (3).
Acute seizures accompanying PRES were a common feature in all early reports of PRES, seen in a remarkably consistent 80 to 90 percent of cases. Most early reports focused on acute presentations and management. But are seizures part of the "reversible" aspect of the syndrome, or in some cases does PRES produce irreversible changes in which the acute seizures herald the development of long-term epilepsy?
Several case reports established that epilepsy is a possible consequence of acute PRES. Baldini OBJECTIVE: Seizures are common in patients with posterior reversible encephalopathy syndrome (PRES), which is reported in up to 70% of cases, and antiepileptic drugs (AEDs) are commonly prescribed. There is a paucity of data regarding the risk of subsequent seizures following resolution of PRES, and therefore the optimal duration of treatment with AEDs is currently unknown. The objective of this study was to identify the frequency of recurrent seizures and epilepsy following recovery from PRES. METHODS: We performed a retrospective review of consecutive adults diagnosed with PRES between 2000 and 2010. RESULTS: One hundred twenty-seven patients, median age 53 years (interquartile range [IQR] 37-64), were included in the analysis. The most common causes of PRES were hypertension (72%) and immunosuppression (20%). Renal failure was present in 47%. Eighty-four patients (66%) had seizures at presentation (39 focal, 45 generalized), and 13 (15%) of them presented with status epilepticus. Median duration of follow-up was 3.2 years (IQR 4 months to 6.9 years). Patients with seizures were treated with AEDs for a median of 3 months (IQR 2-7). Fifteen patients (12%) had provoked seizures during the follow-up period; in eight (53%) patients seizures were caused by recurrent PRES. Only three patients had subsequent unprovoked seizures, one of whom was considered to have developed epilepsy. SIGNIFICANCE: We conclude that unprovoked seizures and epilepsy are uncommon in patients who have recovered from PRES. Discontinuation of AEDs following resolution of PRES should be considered, provided there is adequate control of risk factors, and absence of factors that could substantially lower the seizure threshold.
PRES-ing for Answers About Long-Term Seizure Risk in Patients With Posterior Reversible Encephalopathy Syndrome
PRES following liver transplantation in which the MRI changes of PRES resolved but seizures persisted. Shortly after this, Skiba et al. (5) reported a patient who suffered recurrent episodes of PRES accompanied by posterior dominant periodic epileptiform discharges on EEG who went on to develop epilepsy. Additional single cases reports described development of hippocampal sclerosis and refractory epilepsy following PRES (6, 7) . These cases demonstrated that seizures in PRES might not be a universally reversible feature. But how common was post-PRES epilepsy?
Earlier case series suggested that post-PRES epilepsy was rare but estimates were limited by small sample size. Roth et al. (8) reported long-term outcome in 25 patients following PRES. They noted that clinical symptoms resolved in an average of a week, while imaging resolution lagged, requiring 41 days on average. They concluded that PRES had good short-and longterm prognosis, and reported no cases of new-onset epilepsy. Similarly, Kastrup et al. (9) found that no seizures occurred more than 24 hours after presentation in 49 patients with PRES, and none had experienced recurrence of seizures at 6 months follow-up, including after taper of antiepileptic drugs.
Given the apparent rarity of post-PRES epilepsy, what length of AED therapy is warranted? How should we advise our colleagues and patients?
Datar et al. sought to definitively answer this question from studying a large group of patients with PRES from a single institution. A retrospective database search identified 146 patients with PRES, from which they excluded 19 patients because of previous seizures, other acute CNS lesions, or because inadequate data were available. The remaining 127 patients had clinical features similar to those previously reported, including female predominance and most often hypertension (72%) or immunosuppression (20%) as the presumed etiology. Two-thirds had seizures on presentation, and 15% experienced status epilepticus. A strength of the study was relatively long-term follow-up (median 3.2 years). Because the study was retrospective, there was no predetermined protocol for AED choice or duration of therapy, but levetiracetam and phenytoin were used most commonly, and the median duration of treatment was three months.
The results of their study strongly supported the idea that post-PRES epilepsy is rare. Three patients had single unprovoked seizures outside of the acute presentation, but only one had recurrent unprovoked seizures and a diagnosis of epilepsy. Interestingly, this patient was noted to have periodic lateralized epileptiform discharges (PLEDs) on EEG, a relatively rare finding seen only in 6% of their PRES population. However, another recent report suggests that EEG features, including PLEDs, do not reliably identify the rare PRES patient who goes on to develop epilepsy (10) . Somewhat more common were late provoked seizures, seen in 15 (12%) patients. About half of these were caused by recurrent bouts of PRES, while the other half were provoked by various other factors.
Patients who present acutely with PRES frequently experience seizures, and short-term treatment with AEDs is well-supported. Fortunately, these patients can be reassured that later development of epilepsy is rare, and this work by Datar et al. reinforces the common practice of discontinuing AED therapy, in the absence high-risk features, when the acute phase of PRES has resolved.
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